Technology is enabling new ways of credibly accessing medical knowledge via smart phones / tablets.
Android, iOS have > 5k health / fitness apps like @Medscape, pointing to a future where the Tech. drives a part of medical knowledge and therapeutic guidance instead of a Doctor!
-
Prikaži ovu nit
-
Obviously, this won’t happen 4 all customers and all conditions; poorly understood or serious conditions would still require a Doctor!! But for well-educated patients with MINOR or "Well-Understood" conditions, cost of direct medical advice won’t make any economic sense!!
1 reply 3 proslijeđena tweeta 12 korisnika označava da im se sviđaPrikaži ovu nit -
‘Telemedicine’ offers potential for disintermediation, by transferring medical info either to or from the patient, without direct presence of healthcare professional Even non-pharma firms like
#Vodafone#CiscoSystems are partnering to create real-time patient monitoring systems!3 proslijeđena tweeta 16 korisnika označava da im se sviđaPrikaži ovu nit -
The ‘science fiction’ world of truly personalized medicine was deemed a far-flung opportunity by
@McKinsey research in 2010 (link below). Almost a decade later – this may still be decades away!! (if not impossible to achieve). Excellent read
Source: https://www.mckinsey.com/~/media/McKinsey/dotcom/client_service/Pharma%20and%20Medical%20Products/PDFs/RDemergingmarkets.ashx …1 reply 6 proslijeđenih tweetova 29 korisnika označava da im se sviđaPrikaži ovu nit -
McKinsey's report above suggests that the aim to deliver Personalized-Drugs, no doubt would face significant Technical and Operational issues, BUT the biggest challenges are Economics (not Science!) related
- as huge R&D costs be spread over very thin volumes - not viable?!?!?!1 proslijeđeni tweet 15 korisnika označava da im se sviđaPrikaži ovu nit -
Bioinformatics is becoming a dominant theme in disrupting the conventional Pharma research processes! PwC (below) opines that bioinformatics approaches improve the efficiency of Pharma R&D by enabling drug candidates to "fail fast and fail cheaply". https://www.pwc.com/gx/en/pharma-life-sciences/pdf/pharma2020_virtualrd_final2.pdf …
1 reply 3 proslijeđena tweeta 16 korisnika označava da im se sviđaPrikaži ovu nit -
The practical application of bioinformatics is the increasing development of ‘in silico’ R&D to complement or replace drug development processes that were previously carried out ‘in vivo or in vitro (in animals or labs).
#CDMO#CRO like#syngene see huge potential ahead!!pic.twitter.com/pqTFhyIOA2
9 proslijeđenih tweetova 46 korisnika označava da im se sviđaPrikaži ovu nit -
It's almost mandatory now for a Pharma innovator, Biotech (large or a startup) in the western world to partner with a competent, agile and compliant supplier who not only speaks and understands the same 'language of IP & Innovation' but operates out of a low-cost jurisdiction!pic.twitter.com/xQYwu5HzCV
1 reply 7 proslijeđenih tweetova 26 korisnika označava da im se sviđaPrikaži ovu nit -
Artificial Intelligence represents a key enabler to win the productivity race of speed and cost efficiency.
@Accenture research shows that industry executives view Artificial Intelligence as essential for a successful R&D Operating Model both today and in the future@SyngeneIntlpic.twitter.com/HhryG0TCnr
1 reply 6 proslijeđenih tweetova 19 korisnika označava da im se sviđaPrikaži ovu nit -
Future lab-to-market biopharma innovations will come via global partnerships where innovator & supplier teams collaborate (instead of the traditional fully integrated model). Opportunity in biotech, low-cost commercial-scale production!
#CMO#CRAMS#CROhttps://www.mckinsey.com/Videos/video?vid=5620103642001&plyrid=HkOJqCPWdb …17 proslijeđenih tweetova 52 korisnika označavaju da im se sviđaPrikaži ovu nit
Ready to use next-gen technology platforms and shift in portfolios from large volumes but simple, to lower volumes but complex or orphan molecules or even the lack of approved capacity for complex/sterile drugs are some reasons the #CDMOs have started to feel real +ve traction.
-
-
Disruptions have happened. Will happen again
@arpit971
Explains why
CRAMS/API are much lower risk
Domestic pharma pricing challenges to intensify
India is 'the' superpower in oral dosage
India's problems are in biologics/sterile manufacturinghttps://www.youtube.com/watch?v=PgLKMUDRJik …1 reply 17 proslijeđenih tweetova 42 korisnika označavaju da im se sviđaPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.